BMYBristol-Myers Squibb Co. — stock analysis & sentiment
Bristol-Myers Squibb Co. (BMY) last closed at $63.00, in the upper half of its 52-week range of $42.52–$68.64. Composite market sentiment across 2 analyses is positive (+17 on a −100 to +100 scale), as of Oct 23, 2026.
Produced by the Synoptiv Research Engine from public financial data. Read the methodology.
Go beyond the overview
The thesis, technical signals, risk levels, and complete evidence — everything the overview leaves out.
What changed
Since the previous analysis (v1) on Aug 23, 2026.
BMY fell to $63.00, from $67.01 at the previous analysis.
Composite sentiment ticked down from +21 to +17, still positive.
39 headlines since the last analysis — 16 positive, 6 negative, 17 neutral.
Market cap fell -5.98%, from $136.88B to $128.69B.
The written analysis on this page was refreshed for v2.
What the data says
An overview of the public data behind BMY.
At $63.00, Bristol-Myers Squibb trades in the upper part of its 52-week range of $42.52 to $68.64. That puts it about 78% of the way from the low to the high, roughly 8% below the peak and nearly 50% above the trough. The high is about 60% above the low, which is a wide spread for a large drugmaker, so the stock has made a sizable move over the past year rather than holding steady.
At a market capitalization of about $129 billion, the market prices the company at just under 14 times trailing earnings. On forward earnings that falls to about 9.5 times, meaning analysts expect profits to rise from current levels. The company keeps about 19 cents of profit from each dollar of revenue, and revenue grew 5.7%. The price-to-book ratio is near 5.8, so the market values the business well above its accounting net assets. The dividend yield is 4.0%. A beta of 0.18 means the shares have moved very little with the broader market and have tracked their own drivers more than general market swings.
Most recent news has been comparison pieces that set Bristol-Myers Squibb against peers such as Pfizer, Novo Nordisk and Amgen, framed around revenue consistency and scale. One company-specific article looks at generic competition across its key drug portfolio, and another focuses on its dividend. The rest is sector coverage, including a forecast for the global oral drugs market and pieces on Eli Lilly and Prothena. Overall, the news centers on where Bristol-Myers Squibb stands within the wider pharmaceutical group more than on any single event at the company.
Written from public market data. Research, not financial advice — the thesis, signals and risk levels are in the full report.
Price chart
BMY daily price history.
Market sentiment
A composite of the public market data in this analysis, from −100 (bearish) to +100 (bullish).
This gauge blends news tone, analyst views, insider and congressional activity, and price momentum into a single score. The full report breaks down each driver and pairs it with the thesis.
See the full sentiment breakdown in the report →Key stats
A public snapshot of commonly used market and valuation measures.
Valuation & size
- Market cap
- $128.69B
- Enterprise value
- $162.68B
- P/E (TTM)
- 13.88
- Forward P/E
- 9.54
- Price / book
- 5.77
- Price / sales
- 2.62
Profitability & growth
- Net margin
- 18.87%
- Revenue growth
- +5.70%
- Earnings growth
- +1.53%
- Dividend yield
- 4.00%
Price & risk
- Beta
- 0.18
- Average volume
- 11.76M
From noise to signal. The full report has BMY’s thesis, trade signal, and risk levels.
About Bristol-Myers Squibb Co.
Bristol-Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. Its portfolio spans oncology, hematology, immunology, cardiovascular disease, and neuroscience, and includes the immuno-oncology therapies Opdivo, Yervoy, and Opdualag; the blood thinner Eliquis, marketed with Pfizer; multiple myeloma treatments such as Revlimid, Pomalyst, and the cell therapy Abecma; and the immunology medicines Orencia, Zeposia, and Sotyktu. More recent additions include Camzyos for obstructive hypertrophic cardiomyopathy, Krazati for KRAS G12C-mutated cancers, Reblozyl for anemia, Breyanzi for large B-cell lymphoma, and Cobenfy for schizophrenia. The company sells to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies, and supplements its internal research with licensing agreements and research collaborations, including work with Arcus Biosciences in kidney cancer. Bristol-Myers Squibb traces its roots to 1887 and is headquartered in Princeton, New Jersey.
Latest news
Recent headlines related to BMY, with vendor tone.
BMY — frequently asked questions
Answered from the public data on this page.
What is the current market sentiment for BMY?
As of Oct 23, 2026, Bristol-Myers Squibb Co. (BMY) carries positive (+17 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.
How has BMY stock been performing?
Bristol-Myers Squibb Co. last closed at $63.00, in the upper half of its 52-week range of $42.52–$68.64.
What is BMY's market cap and valuation?
Bristol-Myers Squibb Co. has a market capitalization of about $128.69B, a trailing P/E of 13.9, a dividend yield of 4.00%.
What sector is BMY in, and who are its competitors?
Bristol-Myers Squibb Co. operates in the Healthcare sector, specifically Drug Manufacturers - General. Comparable companies include LLY, JNJ, MRK, PFE, RPRX.
Where can I find a full analysis of BMY?
The full BMY report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.
Analysis history
Every saved analysis, newest first.